CervoMed to present Phase 2a trial biomarker data at ISFTD 2026
CervoMed announced initial 12-week biomarker results from its Phase 2a trial of neflamapimod for nfvPPA will be presented as a late-breaking oral session at the ISFTD conference in October.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day